Geriatric medicine Archives - Page 3 of 6

Clinical Articles

Could the shingles vaccine lower risk of dementia?

A recent study has suggested Shingrix may delay the onset of dementia...

Podcasts

Maintaining muscles of independence – Sarcopenia screening & management – Lecture

Dr Anita Munoz provides a practical framework to help GPs identify and assess older patients with or at risk of sarcopenia and muscle weakness.

Learning Modules

RSV and the Heart

Healthed brings together four leading experts in infectious disease, cardiology, geriatrics and diabetes for a lively, authoritative, cross disciplinary discussion.

Podcasts

Mild Cognitive Impairment – What Can GPs do About it? – Lecture

Dr Mark Hohenberg explains that early intervention often can help.

Videos

Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).¹

Videos

ENSURE – The role of early intervention in muscle health

In this Product Explainer Geriatrician A/Prof Solomon Yu explains the importance of integrating muscle health screening, diagnosis and management in routine clinical practice, and the role of early intervention including HMB enriched oral nutritional supplementation for preventing and reversing sarcopenia.

Clinical Articles

Shingrix FAQ

From 1 November, Shingrix will replace Zostavax on the National Immunisation Program (NIP), with free coverage expanded to people aged ≥65 and First Nations people aged ≥50, as well as immunocompromised people with certain medical conditions who are aged ≥18.

Learning Modules

On-Demand Seminar | Women’s & Children’s Health Update 2023

This value-packed online learning module features a high-quality educational programme presented by leading experts focusing on practical clinical issues you face daily.

Clinical Articles

Topical NSAIDs come out on top for osteoarthritis, but guidelines lag

Topical NSAIDs come out on top for osteoarthritis and musculoskeletal pain, but not all guidelines reflect the evidence

Clinical Articles

Major changes to shingles vaccine program announced

Health minister Mark Butler endorsed the Pharmaceutical Benefit Advisory Committee's recommendation to fund Shingrix on the National Immunisation Programme (NIP)

Clinical Articles

Dementia & MHT – Cause or correlation?

A Danish study has linked HRT to dementia, but experts say the research is far from clearcut

Videos

Influenza vaccines for older adults in the 2023 influenza season

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

Geriatric medicine

Could the shingles vaccine lower risk of dementia?

A recent study has suggested Shingrix may delay the onset of dementia...

Maintaining muscles of independence – Sarcopenia screening & management – Lecture

Dr Anita Munoz provides a practical framework to help GPs identify and assess older patients with or at risk of sarcopenia and muscle weakness.

RSV and the Heart

Healthed brings together four leading experts in infectious disease, cardiology, geriatrics and diabetes for a lively, authoritative, cross disciplinary discussion.

Mild Cognitive Impairment – What Can GPs do About it? – Lecture

Dr Mark Hohenberg explains that early intervention often can help.

Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).¹

ENSURE – The role of early intervention in muscle health

Shingrix FAQ

From 1 November, Shingrix will replace Zostavax on the National Immunisation Program (NIP), with free coverage expanded to people aged ≥65 and First Nations people aged ≥50, as well as immunocompromised people with certain medical conditions who are aged ≥18.

On-Demand Seminar | Women’s & Children’s Health Update 2023

This value-packed online learning module features a high-quality educational programme presented by leading experts focusing on practical clinical issues you face daily.

Topical NSAIDs come out on top for osteoarthritis, but guidelines lag

Topical NSAIDs come out on top for osteoarthritis and musculoskeletal pain, but not all guidelines reflect the evidence

Major changes to shingles vaccine program announced

Health minister Mark Butler endorsed the Pharmaceutical Benefit Advisory Committee's recommendation to fund Shingrix on the National Immunisation Programme (NIP)

Dementia & MHT – Cause or correlation?

A Danish study has linked HRT to dementia, but experts say the research is far from clearcut

Influenza vaccines for older adults in the 2023 influenza season

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

Get the app

Site

Company

Connect

Legal

Healthed

Geriatric medicine

A recent study has suggested Shingrix may delay the onset of dementia...

Dr Anita Munoz provides a practical framework to help GPs identify and assess older patients with or at risk of sarcopenia and muscle weakness.

Healthed brings together four leading experts in infectious disease, cardiology, geriatrics and diabetes for a lively, authoritative, cross disciplinary discussion.

Dr Mark Hohenberg explains that early intervention often can help.

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1

From 1 November, Shingrix will replace Zostavax on the National Immunisation Program (NIP), with free coverage expanded to people aged ≥65 and First Nations people aged ≥50, as well as immunocompromised people with certain medical conditions who are aged ≥18.

This value-packed online learning module features a high-quality educational programme presented by leading experts focusing on practical clinical issues you face daily.

Topical NSAIDs come out on top for osteoarthritis and musculoskeletal pain, but not all guidelines reflect the evidence

Health minister Mark Butler endorsed the Pharmaceutical Benefit Advisory Committee's recommendation to fund Shingrix on the National Immunisation Programme (NIP)

A Danish study has linked HRT to dementia, but experts say the research is far from clearcut

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus

Get the app

Site

Company

Connect

Legal

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Extra Details

Healthed

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).¹